# GlyTR1

Source: https://onco.cc/drugs/glytr1/  
OnCo record `glytr1` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GlyTR1 is an experimental protein from GlyTR Therapeutics that latches onto sugar molecules crowded on cancer cells and pulls immune T cells in to attack. It has been tested only in the laboratory and in animals.

## Summary

GlyTR1 is a bispecific Glycan-dependent T cell Recruiter developed by GlyTR Therapeutics from work at the University of California, Irvine. It binds beta1,6GlcNAc-branched N-glycans through a lectin domain and engages T cells through CD3. The NIH RePORTER abstract for STTR award 4R42CA302415-02 describes GlyTR1 and GlyTR2 as killing cells with high but not low expression of tumour-associated carbohydrate antigens in preclinical models; there are no human results.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: GlyTR1
- Modality: Bispecific T-cell engager (lectin domain fused to anti-CD3)
- Mechanism: A Glycan-dependent T cell Recruiter: a lectin domain binds beta1,6GlcNAc-branched N-glycans, which are dense on many cancer cells, and an anti-CD3 domain brings T cells to kill them.

## Sources

- GlyTR Therapeutics: news: https://glytrtherapeutics.com/news/
- NIH RePORTER: STTR award 4R42CA302415-02: https://reporter.nih.gov/project-details/11457445

## Connected records

- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [GlyTR Therapeutics](https://onco.cc/companies/glytr-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/glytr1.json